Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A study from the Radcliffe Department of Medicine has found that the Athena SWAN scheme tackles multiple factors more comprehensively than other initiatives.

Circular diagram showing Athena Swan domains

Established in the UK in 2005 to encourage and recognise commitment to advancing the careers of women in science, technology, engineering, maths and medicine, Athena SWAN is now widely adopted in the UK and has spread globally. Despite the widespread adoption of Athena SWAN, there is a paucity of research on the design and implementation of Athena SWAN action plans.

So, a team of researchers from Aarhus University, RDM, and the NIHR Oxford Biomedical Research Centre analysed the design and implementation of 16 departmental Athena SWAN Silver action plans in the Medical Sciences Division of the University of Oxford.

The study showed that Athena SWAN is the single most comprehensive gender equality scheme in Europe. RDM’s Pavel Ovseiko explained: “Given that the complex mix of factors produces barriers for women in science, an equally complex intervention is required to address them. Athena SWAN does this more comprehensively than any other single scheme in Europe by focusing systemic interventions on all genders, career stages, and categories of staff. Yet, Athena SWAN can be further strengthened based on Europe’s best practice of Responsible Research and Innovation in promoting the integration of sex and gender analysis in research and education”.

The study interpreted these empirical findings using complexity theory and showed that Athena SWAN Silver action plans conform to the key considerations of complexity such as having multiple actions and areas of intervention, focusing on the local dynamics, the non-linearity of interventions, and the constantly emerging conditions.

Read the full story on the Radcliffe Department of Medicine website

Find out more about Athena SWAN in the Medical Sciences Division

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.